Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLF10 | Q13118 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.33 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.33 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27176949 | 0.84 | IDO1 (0.43) | KLF10IDO1CES2PDE2ASIRT2 | |
| SCHEMBL31085526 | 0.81 | KLF10 (0.44) | KLF10IDO1CYP3A4CYP2D6CES2 | |
| SCHEMBL1014987 | 0.81 | KLF10 (0.44) | KLF10IDO1CYP3A4CYP2D6CES2 | |
| SCHEMBL12650016 | 0.80 | ESR1 (0.40) | IDO1CYP3A4CYP2D6CES2PDE2A | |
| SCHEMBL28035154 | 0.80 | IDO1 (0.40) | IDO1CYP3A4CYP2D6CES2PDE2A | |
| SCHEMBL532671 | 0.80 | IDO1 (0.40) | IDO1CYP3A4CYP2D6CES2PDE2A | |
| SCHEMBL17029998 | 0.80 | KLF10 (0.48) | KLF10CYP2D6KIF11ALDH1A1HPGD | |
| SCHEMBL3827119 | 0.78 | RXRA (0.47) | CES2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1167122 | 0.78 | IDO1 (0.58) | KLF10IDO1CYP3A4CYP2D6PDE2A | |
| SCHEMBL561439 | 0.78 | KLF10 (0.66) | KLF10IDO1CYP2D6SIRT2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973889-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-1973889-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014111953-A1 | PROCESS FOR PREPARATION OF ANACETRAPIB AND INTERMEDIATES THEREOF | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| US-7202364-B2 | Certain phenylacetic acids and derivatives | NOVARTIS, AG (CH) | 2007-04-10 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
| EP-1736465-A1 | ANILINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2006-12-27 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014357-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1567477-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | Novartis AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2004048314-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | KLF10 1176/4885IDO1 4683/4885CYP3A4 446/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | KLF10 1176/4885IDO1 4683/4885CYP3A4 446/4885 |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | KLF10 4211/4885IDO1 442/4885CYP3A4 169/4885 |
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | KLF10 1029/4885IDO1 256/4885CYP3A4 329/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | KLF10 1176/4885IDO1 4683/4885CYP3A4 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.